Colitis can last anywhere from a few days to the rest of your life, depending entirely on what is causing it. A bout of bacterial colitis from contaminated food typically clears within a week or two, while ulcerative colitis is a chronic condition that persists for decades and requires ongoing treatment. Between those extremes sit several other forms of colitis, each with its own timeline, and the line between “acute” and “chronic” is not always obvious in the early weeks.
Bacterial and Other Infectious Colitis
The most common reason for a sudden episode of colitis is infection, usually bacterial. Pathogens like Salmonella, Shigella, Campylobacter, and certain strains of E. coli cause inflammation of the colon lining that shows up as bloody diarrhea, cramping, and sometimes fever. For most otherwise healthy people, these infections are self-limiting, meaning the immune system clears the pathogen and the colon heals without specific treatment within roughly one to two weeks.1PubMed Central. Bacterial colitis Antibiotics become necessary for people who are immunocompromised, very young, very old, or whose infection develops complications like bacteremia. But for the average adult, infectious colitis is the shortest-lived form of the disease.
Clostridioides difficile deserves a special mention. Unlike most bacterial causes, C. diff colitis has a frustrating tendency to recur. A first episode resolves with a course of antibiotics, but somewhere around one in five people experience a relapse, and each recurrence raises the odds of another. What starts as an acute illness can become a months-long cycle of treatment and relapse before finally clearing.
Microscopic Colitis
Microscopic colitis causes persistent watery diarrhea even though the colon looks normal on a standard colonoscopy. The inflammation shows up only under a microscope, in one of two patterns: collagenous colitis or lymphocytic colitis. Its duration sits in an interesting middle zone. One long-term study following patients for a median of about ten years found that roughly 28% of people with microscopic colitis relapsed after initial improvement, with the median time to relapse being about four years after diagnosis.2PubMed Central. Long-Term Natural History of Microscopic Colitis: A Population-Based Cohort That means the majority stayed in remission over that period.
Lymphocytic colitis, one of the two subtypes, seems to have a particularly good outlook. In one study, diarrhea resolved and the colon lining returned to normal in over 80% of patients within about three years.3PubMed. Lymphocytic colitis: clinical presentation and long term course Interestingly, the diagnosis itself can be somewhat unstable over time: about 30% of people who met the microscopic colitis criteria on an initial biopsy no longer did on a repeat biopsy, suggesting that the histological changes can come and go.4PubMed. Microscopic colitis: clinical findings, topography and persistence of histopathological subgroups So while microscopic colitis is not usually a one-week illness like food poisoning, it is also not the lifelong commitment that ulcerative colitis demands.
Radiation Colitis
Radiation therapy aimed at pelvic or abdominal cancers can damage the colon in two distinct waves. Acute radiation colitis develops during or shortly after treatment and is mostly self-limiting, usually resolving with supportive care once radiation ends. Chronic radiation colitis is a different animal entirely. It can appear anywhere from six months to five years after radiation treatment and tends to be progressive, causing fibrosis, narrowing, fragility of the colon wall, and sometimes obstruction.5PubMed Central. Recent advances in the management of radiation colitis Because the damage stems from permanent changes to blood vessels and tissue structure rather than ongoing infection or immune attack, chronic radiation colitis does not follow the flare-and-remission pattern of inflammatory bowel disease. It is a slow, accumulating injury.
Drug-Induced Colitis From Cancer Immunotherapy
A newer and increasingly recognized form of colitis comes from immune checkpoint inhibitor drugs used to treat cancers. These medications work by unleashing the immune system against tumors, but the same unleashed immune response can turn on the colon. Gastrointestinal side effects typically develop about six to eight weeks after starting the drugs, though a European study found the median onset was about four months.6PubMed Central. Diagnosis and Management of Immune Checkpoint Inhibitor Colitis7PubMed. A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium
What makes this form of colitis unusual from a duration standpoint is that it can appear months after the immunotherapy has been stopped. One case report documented significant colitis developing four months after the last dose of pembrolizumab.8PubMed Central. Immune Checkpoint Inhibitor-Induced Colitis: How Long Does the Threat Last? The colitis itself typically resolves with steroids and sometimes other immunosuppressants, but the window during which it can strike is surprisingly long, and some patients develop a chronic course that requires ongoing management.
Ulcerative Colitis and Crohn’s Disease
When most people worry about colitis lasting “a long time,” they are really asking about inflammatory bowel disease. Ulcerative colitis and the colonic form of Crohn’s disease are chronic conditions with no definitive cure. They follow a relapsing-remitting pattern: stretches of active disease (flares) alternate with periods of relative quiet (remission). Patients themselves describe flares as sustained periods of gastrointestinal symptoms that cycle with remission in a recurring pattern.9PubMed Central. Patient Understanding of “Flare” and “Remission” of Inflammatory Bowel Disease
Ulcerative colitis in particular is characterized by dependence on corticosteroids to achieve remission, especially early in the disease course.10PubMed Central. Explainable artificial intelligence for prediction of refractory ulcerative colitis: analysis of a Japanese Nationwide Registry The challenge is that each person’s trajectory is wildly variable. Some people have a single severe flare followed by years of quiet. Others cycle through flares every few months. And a subset develop refractory disease that does not respond well to standard therapies. There is no reliable way to predict at diagnosis which path a given person will follow, though research into predictive tools is active.
Crohn’s disease affecting the colon adds the risk of progressive structural damage. A study of colonic strictures in Crohn’s found that surgery-free survival was about 59% at six months but dropped to roughly 32% at five years, meaning that over time, a substantial share of patients with Crohn’s colonic strictures eventually needed an operation.11Future Science OA. Colonic strictures in Crohn’s disease: a non-surgical survival Biologic therapy was the strongest protective factor against needing surgery.
What Drives Colitis to Become Chronic
The difference between colitis that resolves and colitis that becomes a lifelong problem often comes down to whether the gut’s structural and microbial defenses can fully recover. In inflammatory bowel disease, the intestinal barrier becomes “leaky,” allowing bacteria and their byproducts to cross from the inside of the gut into the wall, where they trigger waves of immune activation.12Experimental & Molecular Medicine. Mechanisms regulating intestinal barrier integrity and its pathological implications Research shows that even when the proteins making up the intestinal barrier are otherwise normal, functional abnormalities in how they seal the gut lining can be enough to sustain disease.
The gut microbiome plays a parallel role. In people with IBD, the mix of bacteria living in the colon is significantly different from that of healthy individuals, and this remains true even during remission, when symptoms have quieted down.13PubMed Central. Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission Certain bacterial families persist during quiet periods and appear to drive chronic inflammation when conditions shift. Meanwhile, a disrupted microbiome can reduce immune tolerance and trigger abnormal immune responses on its own.14Digestive Diseases. Gut Microbiome Dysbiosis and Inflammatory Bowel Disease Complement Each Other The result is a feedback loop: barrier damage lets bacteria through, bacteria inflame the tissue, inflammation further damages the barrier. Once that cycle is established, it becomes self-sustaining, which is a large part of why IBD is chronic.
When Symptoms Linger After the Infection Has Cleared
Even acute colitis that resolves on paper can leave a lasting mark. Post-infectious irritable bowel syndrome is a recognized condition in which symptoms like cramping, diarrhea, and urgency persist long after the original pathogen is gone.15PubMed Central. Post-infectious irritable bowel syndrome The symptoms are real, but they are driven by changes in how the gut nerves and muscles function rather than by ongoing infection or visible inflammation.
The timeline can be discouraging. Both the microscopic tissue changes and the symptoms may persist for years, with one study finding that only about 40% of affected individuals recovered over a six-year follow-up.16Gastroenterology. Postinfectious irritable bowel syndrome So while the colitis itself may have lasted a week, its functional aftereffects can stretch on much longer. This is one reason people sometimes feel that their colitis “never really went away” even when tests come back normal.
How Modern Treatment Shapes Remission
The duration of active disease in IBD has shortened considerably since the arrival of biologic and small-molecule therapies. A meta-analysis of randomized trials found that among people with ulcerative colitis who responded to initial treatment and were kept on active medication, roughly 40% maintained clinical remission, compared with about 18% on placebo.17PubMed. Maintenance of clinical remission with biologics and small molecules in inflammatory bowel disease according to trial design: Meta-analysis The newer drugs also differ from each other. A network meta-analysis found that certain small-molecule therapies outperformed most biologics at maintaining both endoscopic and microscopic healing in ulcerative colitis.18Journal of Crohn’s and Colitis. P879 Comparative Efficacy of Biologics and Small Molecule Therapies for the Induction and Maintenance of Endoscopic and Histological Remission in Ulcerative Colitis
The practical meaning for you: starting effective maintenance therapy early and sticking with it can keep flares shorter and less frequent. But roughly half of people on these drugs still experience some disease activity, and no current therapy “cures” IBD. Treatment buys remission. It does not end the disease.
Tracking Whether Inflammation Is Actually Resolving
One of the frustrations of colitis is that symptoms and actual inflammation do not always line up. You can feel better while your colon is still inflamed, or feel terrible while it is healing. Fecal calprotectin, a protein released by white blood cells in the gut, has become a useful non-invasive way to monitor what is happening beneath the surface. In one study of people with active ulcerative colitis, the time for calprotectin levels to drop to a range consistent with mucosal healing ranged from two to ten months, with a median of four months.19PubMed Central. Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis
Calprotectin also helps predict whether remission will hold. Research has found that levels above a certain threshold while in clinical remission predicted relapse at both six and twelve months, while very low levels corresponded with true histological quiet in the colon.20Inflammatory Bowel Diseases. Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis For the person living with colitis, this means that a falling calprotectin level after a flare is genuinely reassuring, while a stubbornly high level is a signal that treatment may need adjusting before symptoms return.
The Long-Term Price of Persistent Inflammation
The reason duration matters so much in colitis is not just about how long you feel unwell. In ulcerative colitis, the cumulative burden of inflammation over time significantly raises the risk of colorectal cancer. The overall risk is estimated at roughly 2% after ten years of disease, 8% after twenty years, and 18% after thirty years.21PubMed Central. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies The total amount of inflammation over time matters more than any single snapshot. A large single-center study found that the cumulative inflammatory burden was significantly associated with the development of colorectal neoplasia, and that the average severity of inflammation measured across all colonoscopies over the preceding five years was a much better predictor of cancer risk than what any single recent scope showed.22PubMed. Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study
This is the strongest argument for aggressive treatment even when symptoms feel manageable. Smoldering low-grade inflammation that you barely notice still accumulates biological damage over years. Keeping inflammation truly suppressed, not just keeping symptoms quiet, is what reduces long-term cancer risk.
Severe acute colitis also carries immediate dangers. Toxic megacolon, a life-threatening complication in which the colon dilates and the patient becomes systemically ill, can occur during any severe flare of IBD or certain infections. It requires emergency treatment and surgery in the majority of cases.23PubMed Central. Toxic Megacolon: Background, Pathophysiology, Management Challenges and Solutions
How Childhood-Onset Colitis Behaves Differently
Children diagnosed with colitis tend to have a different disease course than adults. In a Korean multicenter study, patients diagnosed before age 18 more frequently had Crohn’s disease rather than ulcerative colitis, and when they did have UC, it was more likely to involve the entire colon. Younger patients also had higher rates of malnutrition and perianal complications at diagnosis.24PubMed Central. Long-term clinical course, treatment patterns, and prognosis in pediatric-onset vs. adult-onset IBD: a multicenter retrospective cohort study in Korea
A systematic review of pediatric IBD natural history found that extensive colitis was present in nearly twice as many children with UC compared with adults, and the time to needing surgery was significantly shorter in children.25PubMed Central. Natural History of Pediatric-onset Inflammatory Bowel Disease A Systematic Review At the same time, among children with Crohn’s disease, the proportion ultimately requiring surgery was actually lower than in adults, suggesting that the biology driving early-onset disease may be somewhat distinct. In practical terms, children diagnosed with colitis tend to need earlier and sometimes more aggressive treatment, and families should expect that the disease may behave more extensively than a typical adult case.
What Happens After Surgery
For people with ulcerative colitis who ultimately need their colon removed, the standard procedure creates an internal pouch from the small intestine. This is often described as a “cure” for UC, but it is not quite that simple. Pouchitis, inflammation of the surgically created pouch, is the most common complication and affects up to about 80% of patients, with around 40% developing it within the first year.26PubMed Central. Medical treatment of pouchitis: a guide for the clinician Risk factors include having had extensive colitis before surgery and certain autoimmune conditions. Most cases of pouchitis respond to antibiotics, but a subset becomes chronic and requires ongoing immunosuppressive treatment. So even after removing the entire colon, the story of colitis duration does not always end.
Environmental Triggers and Geographic Patterns
Where you live and what you are exposed to also influence how IBD behaves. Inflammatory bowel disease rates have been rising globally, and the geographic variability is striking. In Europe, incidence rates in eastern countries have risen to match those in western countries, though the disease at diagnosis tends to be less complicated in the east, with lower rates of surgery and colorectal cancer.27PubMed Central. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies Within individual countries, north-south gradients in disease rates have been documented in the United States, France, and several other nations, pointing to environmental exposures as a major modifier of disease risk and possibly course.
Psychological stress, diet, disrupted sleep, and infections have all been identified as factors that can trigger flares in people who already have IBD.28Frontiers. Stress Triggers Flare of Inflammatory Bowel Disease in Children and Adults None of these cause colitis on their own, but they can determine how long a flare lasts and how quickly the next one arrives. For the person managing chronic colitis, these modifiable triggers represent one of the few areas where personal choices can measurably influence disease duration between flares.